Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection

Phase1 Study of Recombinant Stem Cells That Repair Lung Injury in H7N9 Infected Patients

Status

UNKNOWN

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02095444

Enrollment

Registered

2014-03-24

Start date

2014-03-31

Completion date

2016-12-31

Last updated

2014-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Lung Injury, Acute Respiratory Distress Syndrome (ARDS), Multiple Organ Failure

Brief summary

The purpose of this study is to determine whether human menstrual blood-derived stem cells are effective in the treatment of infection of H7N9 virus caused acute lung injury.

Detailed description

1. recruiting volunteers of H7N9 infection: age \> 18; patients signed with the informed consent; APACHE II \> 20 score 2. patients infused with menstrual blood progenitor cells infusion dose: 1\ 10×10\*7 cells/kg infusion frequency: 2 times a week, 2 weeks for infusion 3. test items and standard spirits lifted; pulmonary function improved; lung image injury improved

Interventions

DRUGMenstrual blood stem cells

10\*7 cells/kg, intravenous injection for 4 times during two weeks

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Clinical diagnosis of H7N9 infection * must be critical injured for lung tissues

Exclusion criteria

* cancer diseases * pregnancy * mental disorder * allergic constitution * severe inflammation

Design outcomes

Primary

Measure	Time frame
The degree of lung injury	14 days

Countries

China

Contacts

Primary ContactCharle Xiang, Doctor

cxiang@zju.edu.cn86-571-87236426

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026